keyword
MENU ▼
Read by QxMD icon Read
search

Anaplastic astrocytoma

keyword
https://www.readbyqxmd.com/read/28801187/benefit-with-adjuvant-chemotherapy-in-anaplastic-astrocytoma
#1
David Schiff
No abstract text is available yet for this article.
August 8, 2017: Lancet
https://www.readbyqxmd.com/read/28791452/long-term-daily-temozolomide-with-dose-dependent-efficacy-in-mgmt-promotor-methylation-negative-recurrent-high-grade-astrocytoma
#2
Zhengqiu Zhou, Tracy A Howard, John L Villano
Temozolomide (TMZ) for malignant gliomas is traditionally dosed in 5 out of a 28-day cycle, however alternative regimens exist, including dose-dense. Continuous daily dosing is available, but the acceptable dose and duration of therapy is unknown. We document a 40-year-old male with recurrent anaplastic astrocytoma, IDH mutant and MGMT promotor methylation negative, who has well-tolerated continuous daily TMZ for 20 months at 100 mg per day for nearly the length of this period. A trial at 80 mg per day demonstrated disease progression with response upon return to 100 mg per day...
August 8, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28782849/diffuse-glioma-rare-homozygous-idh-point-mutation-is-it-an-oncogenetic-mechanism
#3
Angad Singh, Mamta Gurav, Sandeep Dhanavade, Omshree Shetty, Sridhar Epari
Isocitrate dehydrogenase (IDH1/IDH2) mutations in gliomas of WHO grade II/III and secondary glioblastoma are almost always heterozygous missense mutations. Here, we report an extremely rare case of homozygous IDH1R132H mutation in a recurrent WHO grade III anaplastic astrocytoma. The authors here also review the relevant literature for the possible metabolic impact of homozygous IDH1/2 mutations in the gliomagenesis.
August 7, 2017: Neuropathology: Official Journal of the Japanese Society of Neuropathology
https://www.readbyqxmd.com/read/28751444/pediatric-phase-1-trial-and-pharmacokinetic-study-of-trebananib-in-relapsed-solid-tumors-advl1115-a-children-s-oncology-group-phase-1-consortium-report
#4
Sarah E S Leary, Julie R Park, Joel M Reid, Andrew T Ralya, Sylvain Baruchel, Bing Wu, Timothy P L Roberts, Xiaowei Liu, Charles G Minard, Elizabeth Fox, Brenda J Weigel, Susan Blaney
Trebananib is a first-in-class anti-angiogenic peptibody (peptide-Fc fusion protein) that inhibits Angiopoietin 1 and 2. A pediatric phase 1 trial was performed to define trebananib dose limiting toxicities (DLT), recommended phase 2 dose (RP2D) and pharmacokinetics (PK).<br /><br />Experimental Design: Trebananib was administered by weekly infusion. Three dose levels (10, 15 or 30 mg/kg/dose) were evaluated using a rolling-six design. Part 2 evaluated a cohort of subjects with primary central nervous system (CNS) tumors...
July 27, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28744829/early-initiation-of-chemoradiation-following-index-craniotomy-is-associated-with-decreased-survival-in-high-grade-glioma
#5
Jay K Nathan, Amanda L Brezzell, Michelle M Kim, Denise Leung, D Andrew Wilkinson, Shawn L Hervey-Jumper
The Stupp protocol of post-resection external beam radiation therapy and concomitant temozolomide is the standard of care for patients with newly-diagnosed glioblastoma, with expanded use in anaplastic astrocytoma. However, the optimal interval between surgery and these adjuvant therapies, and its impact on survival, is unknown. To investigate this, de-identified claims from a large, private health insurance database were queried to identify adult patients who underwent index craniotomy for resection of a supratentorial neoplasm during the period 2005-2014 and began postoperative radiation and temozolomide within 13 weeks of surgery...
July 25, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28740448/evaluation-of-brain-edema-formation-defined-by-mri-after-linac-based-stereotactic-radiosurgery
#6
Maciej Harat, Andrzej Lebioda, Judyta Lasota, Roman Makarewicz
BACKGROUND: Peri-lesional edema is a serious and well-known complication of stereotactic radiosurgery (SRS). Here we evaluated edema risk after SRS and assessed its formation and resolution dynamics. PATIENTS AND METHODS: 107 patients underwent SRS for heterogeneous diagnoses: 34 (29%) with arteriovenous malformations, 38 (35%) with meningiomas, 16 (15%) with metastatic tumors, 16 (15%) with acoustic neuromas, 3 with (3%) cavernomas, and 2 (2%) each with anaplastic astrocytomas and anaplastic oligoastrocytomas...
June 2017: Radiology and Oncology
https://www.readbyqxmd.com/read/28737579/prostate-specific-membrane-antigen-targeted-imaging-with-18f-dcfpyl-in-high-grade-gliomas
#7
Roberto Andres Salas Fragomeni, Joshua R Menke, Matthias Holdhoff, Clare Ferrigno, John Joseph Laterra, Lilja B Solnes, Mehrbod S Javadi, Zsolt Szabo, Martin G Pomper, Steven P Rowe
High-grade gliomas (World Health Organization grade III-IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)-targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients...
July 22, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28717891/surgery-for-spinal-intramedullary-tumors-technique-outcome-and-factors-affecting-resectability
#8
Sherif Rashad, Amr Elwany, Ahmed Farhoud
Intramedullary spinal cord tumors (IMSCTs) are relatively infrequent lesions with ependymomas and astrocytomas representing the most common types. Microsurgical resection is established as the treatment of choice for these challenging lesions. We reviewed the surgical outcome of 29 cases operated for IMSCTs by the same surgeon between 2009 and 2015. The median follow-up period was 31 months, and all patients were followed up at least for 1 year. Among these 29 cases, 5 patients were previously operated for partial resection elsewhere...
July 17, 2017: Neurosurgical Review
https://www.readbyqxmd.com/read/28708937/malignant-central-nervous-system-tumors-among-adolescents-and-young-adults-15-39-years-old-in-14-southern-eastern-european-registries-and-the-us-surveillance-epidemiology-and-end-results-program-mortality-and-survival-patterns
#9
Marios K Georgakis, Paraskevi Papathoma, Anton Ryzhov, Snezana Zivkovic-Perisic, Sultan Eser, Łukasz Taraszkiewicz, Mario Sekerija, Tina Žagar, Luis Antunes, Anna Zborovskaya, Joana Bastos, Margareta Florea, Daniela Coza, Anna Demetriou, Domenic Agius, Rajko M Strahinja, Marios Themistocleous, Maria Tolia, Spyridon Tzanis, George A Alexiou, Panagiotis G Papanikolaou, Panagiotis Nomikos, Maria Kantzanou, Nick Dessypris, Apostolos Pourtsidis, Eleni T Petridou
BACKGROUND: Unique features and worse outcomes have been reported for cancers among adolescents and young adults (AYAs; 15-39 years old). The aim of this study was to explore the mortality and survival patterns of malignant central nervous system (CNS) tumors among AYAs in Southern-Eastern Europe (SEE) in comparison with the US Surveillance, Epidemiology, and End Results (SEER) program. METHODS: Malignant CNS tumors diagnosed in AYAs during the period spanning 1990-2014 were retrieved from 14 population-based cancer registries in the SEE region (n = 11,438)...
July 14, 2017: Cancer
https://www.readbyqxmd.com/read/28691414/serum-levels-of-vascular-endothelial-growth-factor-vegf-and-basic-fibroblast-growth-factor-bfgf-in-children-with-brain-tumours
#10
Grażyna Sobol-Milejska, Agnieszka Mizia-Malarz, Katarzyna Musiol, Jerzy Chudek, Maria Bożentowicz-Wikarek, Halina Wos, Marek Mandera
BACKGROUND: Angiogenesis is a process of new vessel formation originating from the already present vascular network. It plays an important role in the growth and spreading of malignancies, including brain tumours. Process of angiogenesis is characterised by increased expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and release of their soluble forms into circulation. OBJECTIVES: The aim of the study was to evaluate serum levels of VEGF and bFGF in children with malignant and benign brain tumours...
June 27, 2017: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/28690586/modulations-in-the-peripheral-immune-system-of-glioblastoma-patient-is-connected-to-therapy-and-tumor-progression-a-case-report-from-the-immo-glio-01-trial
#11
Paul F Rühle, Nicole Goerig, Roland Wunderlich, Rainer Fietkau, Udo S Gaipl, Annedore Strnad, Benjamin Frey
Immune responses are important for efficient tumor elimination, also in immune privileged organs such as the brain. Fostering antitumor immunity has therefore become an important challenge in cancer therapy. This cannot only be achieved by immunotherapies as already standard treatments such as radiotherapy and chemotherapy modify the immune system. Consequently, the understanding of how the tumor, the tumor microenvironment, and immune system are modulated by cancer therapy is required for prognosis, prediction, and therapy adaption...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/28675067/postoperative-neoadjuvant-temozolomide-before-radiotherapy-versus-standard-radiotherapy-in-patients-60-years-or-younger-with-anaplastic-astrocytoma-or-glioblastoma-a-randomized-trial
#12
Annika Malmström, Hans Skovgaard Poulsen, Bjørn Henning Grønberg, Giuseppe Stragliotto, Steinbjørn Hansen, Thomas Asklund, Birgitta Holmlund, Małgorzata Łysiak, Joseph Dowsett, Bjarne Winther Kristensen, Peter Söderkvist, Johan Rosell, Roger Henriksson
INTRODUCTION: A pilot study of temozolomide (TMZ) given before radiotherapy (RT) for anaplastic astrocytoma (AA) and glioblastoma (GBM) resulted in prolonged survival compared to historical controls receiving RT alone. We therefore investigated neoadjuvant TMZ (NeoTMZ) in a randomized trial. During enrollment, concomitant and adjuvant radio-chemotherapy with TMZ became standard treatment. The trial was amended to include concurrent TMZ. PATIENTS AND METHODS: Patients, after surgery for GBM or AA, age ≤60 years and performance status (PS) 0-2, were randomized to either 2-3 cycles of TMZ, 200 mg/m(2) days 1-5 every 28 days, followed by RT 60 Gy in 30 fractions or RT only...
July 4, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28640702/diffuse-infiltrating-oligodendroglioma-and-astrocytoma
#13
Martin J van den Bent, Marion Smits, Johan M Kros, Susan M Chang
The new 2016 WHO brain tumor classification defines different diffuse gliomas primarily according to the presence or absence of IDH mutations ( IDH-mt) and combined 1p/19q loss. Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors. IDH-mt tumors have a more favorable prognosis, and tumors with low-grade histology especially tend evolve slowly. IDH-wt tumors are not a homogeneous entity and warrant further molecular testing because some have glioblastoma-like molecular features with poor clinical outcome...
July 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28629398/anaplastic-astrocytoma-mimicking-progressive-multifocal-leucoencephalopathy-a-case-report-and-review-of-the-overlapping-syndromes
#14
Ema Kantorová, Michal Bittšanský, Štefan Sivák, Eva Baranovičová, Petra Hnilicová, Vladimír Nosáľ, Daniel Čierny, Kamil Zeleňák, Wolfgang Brück, Egon Kurča
BACKGROUND: Co-occurrence of multiple sclerosis (MS) and glial tumours (GT) is uncommon although occasionally reported in medical literature. Interpreting the overlapping radiologic and clinical characteristics of glial tumours, MS lesions, and progressive multifocal leukoencephalopathy (PML) can be a significant diagnostic challenge. CASE PRESENTATION: We report a case of anaplastic astrocytoma mimicking PML in a 27-year-old patient with a 15-year history of MS...
June 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28592077/-clinical-effects-of-microsurgery-in-spinal-cord-anaplastic-astrocytoma
#15
L Zhang, W Q Jia, D S Kong, Z F Zhang, J Yang
Objective: To investigate the surgical outcomes and prognosis of spinal cord anaplastic astrocytoma (AA). Methods: A total of 27 consecutive patients diagnosed as spinal cord AA between January 2008 and May 2015 in Department of Neurosurgery of Beijing Tiantan Hospital were retrospectively reviewed. There were 18 males and 9 females, the mean age was (30.7±13.0) years (ranging from 5 to 52 years). The lesions were located at cervical level in 8 patients, at thoracic level in 9 patients, at cervicothoracic level in 3 patients, and at thoracolumbar level in 7 patients, the average number of vertebral was 3...
June 1, 2017: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/28591062/extracranial-bone-metastases-from-recurrent-anaplastic-astrocytoma-on-fdg-pet-ct-a-case-report-a-care-compliant-article
#16
Zu-Gui Li, Hai-Yu Mu
OBJECTIVE: Extracranial bone metastases from astrocytoma are rare and frequently detected as part of multiorgan metastases. It is extremely rare for astrocytoma to have extracranial bone metastases alone. The importance of whole-body fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) imaging in evaluating extracranial metastasis (ECMs) has not been described effectively due to the rarity of this event. The purpose of our case report is to emphasize the role of FDG PET/CT in the assessment of tumor recurrence and extracranial bone metastases from anaplastic astrocytoma...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28587939/temozolomide-and-sorafenib-as-programmed-cell-death-inducers-of-human-glioma-cells
#17
Joanna Jakubowicz-Gil, Dorota Bądziul, Ewa Langner, Iwona Wertel, Adrian Zając, Wojciech Rzeski
BACKGROUND: Gliomas are aggressive brain tumors with very high resistance to chemotherapy. Therefore, the aim of the present study was to investigate the effectiveness of sorafenib and Temozolomide in elimination of human glioma cells through apoptosis and autophagy. METHODS: MOGGCCM (anaplastic astrocytoma) and T98G (glioblastoma multiforme) cell lines incubated with sorafenib and/or Temozolomide were used in the experiments. Cell morphology (ER stress, apoptosis, autophagy, and necrosis) was analyzed microscopically while apoptosis and mitochondrial membrane potential were assessed with flow cytometry...
March 14, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28571159/anaplastic-pleomorphic-xanthoastrocytoma-in-a-case-of-neurofibromatosis-type-1-a-case-report
#18
K Thara, Reetika Sharma, G Thiagarajan, Anita Ramdas, Renu Gboy Varghese
Pleomorphic Xanthoastrocytoma (PXA) is a rare brain tumour comprising only <1% of primary brain tumours which is seen in children and young adults. Only 9-20% of the PXA shows anaplastic features and this has a bad prognosis. PXA is a WHO grade II tumour while anaplastic PXA is a WHO grade III tumour. Neurofibromatosis type 1(NF1), which is an autosomal dominant condition, predisposes to tumours of the central nervous system; most of which are pilocytic astrocytomas. Association of PXA with NF1 is very rare and only a very few cases have been reported...
April 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28512257/comparison%C3%A2-of-chemoradiotherapy%C3%A2-with-radiotherapy-alone-for-biopsy-only-anaplastic-astrocytoma
#19
Jing Wu, Ting Zou, Harrison Xiao Bai, Xuejun Li, Zishu Zhang, Bo Xiao, MacLean Nasrallah, Giorgos Karakousis, Ya Cao, Paul J Zhang, Li Yang
BACKGROUND: It has become increasingly common to incorporate adjuvant chemotherapy with radiotherapy in the treatment of resected anaplastic astrocytoma based on results from recent phase II/III randomized trials. However, whether or not combined chemoradiotherapy is associated with improved survival outcome in patients who undergo "biopsy only" is less clear. METHODS: The US National Cancer Data Base was used to identify patients with histologically confirmed, biopsy-only anaplastic astrocytoma who received either radiotherapy alone or combined chemoradiotherapy from 2006 through 2014...
April 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28508327/assessment-of-molecular-markers-demonstrates-concordance-between-samples-acquired-via-stereotactic-biopsy-and-open-craniotomy-in-both-anaplastic-astrocytomas-and-glioblastomas
#20
Florian Gessler, Peter Baumgarten, Joshua D Bernstock, Patrick Harter, Stephanie Lescher, Christian Senft, Volker Seifert, Gerhard Marquardt, Lutz Weise
The classification, treatment and prognosis of high-grade gliomas has been shown to correlate with the expression of molecular markers (e.g. MGMT promotor methylation and IDH1 mutations). Acquisition of tumor samples may be obtained via stereotactic biopsy or open craniotomy. Between the years 2009 and 2013, 22 patients initially diagnosed with HGGs via stereotactic biopsy, that ultimately underwent open craniotomy for resection of their tumor were prospectively included in an institutional glioma database...
June 2017: Journal of Neuro-oncology
keyword
keyword
57639
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"